Burcon NutraScience reported fiscal 2Q27 revenue of C$1.04M, up 191% y/y but down 18% sequentially, as steam and water disruptions constrained production at its Galesburg facility. Protein sales increased to C$0.80M, while management indicated that production has recovered since quarter-end and expects shipments to rebound in fiscal 3Q. The Company continues to advance its commercial pipeline of 209 active projects, including 26 that have progressed beyond pallet-sized orders, providing opportunities for larger repeat purchases as manufacturing reliability improves. Burcon ended the quarter with C$1.0M in cash and subsequently fully drew its C$4.2M related-party bridge loan, while a proposed convertible financing of up to C$21M remains pending. Looking ahead, continued order conversion, improving production efficiency, and resolution of the December secured-debt maturity remain important considerations as Burcon works toward its objective of positive cash flow in calendar 2027.